What is COGT's current stock price?

COGT (Cogent Biosciences, Inc.) is currently trading at $32.67 with a market cap of $5.58B.

What sector is Cogent Biosciences, Inc. in?

Cogent Biosciences, Inc. (COGT) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is COGT a good stock to buy?

Analysts have a Buy consensus on COGT with a price target of $50.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

COGT Cogent Biosciences, Inc.

Healthcare

$32.67+0.28%ClosedMarket Cap: $5.58B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.62

P/S

0.00

EV/EBITDA

-15.41

DCF Value

$0.74

FCF Yield

-5.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-83.3%

ROA

-39.2%

ROIC

-42.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-97.4M	$—
Q4 null	$0.00	$-102.5M	$—
FY null	$0.00	$-328.9M	$—
Q3 null	$0.00	$-80.9M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$50.00

Target (Median)

$52.00

Target Range

$35.00 - $60.00

2 Strong Buy9 Buy2 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-05-06

WedbushOutperform

2026-03-17

Piper SandlerOverweight

2026-02-18

WedbushOutperform

2026-01-21

HC Wainwright & Co.Buy

2026-01-06

Trading Activity

Insider Trades

View All

Robbins Andrew Rdirector, officer: President and CEO

SellThu May 21

Ferrante Karen Jeandirector

SellFri Apr 03

Fairmount Funds Management LLCdirector

SellTue Mar 31

Fairmount Funds Management LLCdirector

SellTue Mar 31

Fairmount Funds Management LLCdirector

SellTue Mar 31

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.37

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Peers